Abstract
Dyslipidemia is a key factors contributing to the high risk of cardiovascular disease (CVD) in diabetes and its management is of prime importance. However there are a number of controversies in this area which are dealt with in this chapter. One of these is the extent to which diabetes increases CVD risk, which turns out to vary considerably. A second question deals with the preferred dietary and other weight loss therapies and their benefits in dyslipidemic subjects. The third topic discussed deals with the question of “how low to go” with LDL-cholesterol lowering, and in a fourth issue the indications and approach to the use of second or third lipid-modifying agents in combination with statin therapy is discussed. Finally the controversial issue of whether apolipoprotein or lipoprotein subfraction measurements add to the value of the standard lipid profile is debated.